164 related articles for article (PubMed ID: 1240830)
1. [Behavior pharmacology of maprotiline, a new antidepressant].
Ueki S; Fujiwara M; Inoue K; Kataoka Y; Ibii N
Nihon Yakurigaku Zasshi; 1975 Nov; 71(8):789-815. PubMed ID: 1240830
[TBL] [Abstract][Full Text] [Related]
2. [Behavioral pharmacology of a new antidepressant, lopramine].
Ueki S; Fujiwara M; Inoue K
Nihon Yakurigaku Zasshi; 1976 Jul; 72(5):585-607. PubMed ID: 1033109
[TBL] [Abstract][Full Text] [Related]
3. [Behavioral pharmacological properties of the novel antidepressant paroxetine, a selective 5-HT uptake inhibitor].
Yamamoto T; Shibata S; Shimazoe T; Iwasaki K; Ohno M; Minamoto Y; Furuya Y; Miyamoto K; Watanabe S; Ueki S
Nihon Yakurigaku Zasshi; 1989 Sep; 94(3):189-206. PubMed ID: 2530142
[TBL] [Abstract][Full Text] [Related]
4. [Behavioral effects of quinupramine, a new tricyclic antidepressant].
Ueki S; Yamamoto T; Shimazoe T; Shibata S; Tani Y; Machida K; Hojo M; Yoshida Y; Tatsumi H
Nihon Yakurigaku Zasshi; 1988 Jun; 91(6):359-69. PubMed ID: 3417209
[TBL] [Abstract][Full Text] [Related]
5. Experimental evaluation of the antidepressant and neuroleptic activity of maprotiline.
Balsara JJ; Nandal NV; Mane VR; Chandorkar AG
Indian J Physiol Pharmacol; 1982; 26(3):183-95. PubMed ID: 6129195
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological studies of drug action on CNS, with special reference to effects of maprotiline.
Shibuya T; Matsuda H; Endo T; Chen PO; Sato K; Nishimori T
Int J Clin Pharmacol Biopharm; 1975 Apr; 11(3):192-204. PubMed ID: 1171084
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of 9-gamma-methylaminopropyl-9,10-dihydro-9,10-methanoanthracene-HCl (ID-9206-HCl), a new potent antidepressant.
Fukushima H; Nakamura M; Yamamoto H
Arch Int Pharmacodyn Ther; 1977 Sep; 229(1):163-76. PubMed ID: 931463
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological comparison of the potential antidepressant UP 614-04 with viloxazine and imipramine; behavioral studies.
Meignen J; Grognet A; Deniard MJ; Dalphrase F; Roux E; DeFeudis FV
Gen Pharmacol; 1982; 13(5):381-91. PubMed ID: 6890919
[TBL] [Abstract][Full Text] [Related]
9. [Psychopharmacological effects of doxepin hydrochloride].
Ueki S; Ogawa N; Watanabe S; Gomita Y; Araki Y
Nihon Yakurigaku Zasshi; 1972 Nov; 68(6):716-61. PubMed ID: 4676614
[No Abstract] [Full Text] [Related]
10. Some aspects of the psychopharmacological activity of maprotiline (Ludiomil): effects of single and repeated treatments.
Delini-Stula A; Radeke E; Vassout A
J Int Med Res; 1978; 6(6):421-9. PubMed ID: 102548
[No Abstract] [Full Text] [Related]
11. [Behavioral pharmacology of mianserin hydrochloride, a new antidepressant (author's transl)].
Kamioka T; Sakai Y
Nihon Yakurigaku Zasshi; 1980 Sep; 76(6):533-47. PubMed ID: 7193623
[TBL] [Abstract][Full Text] [Related]
12. [Behavioral pharmacology of amantadine with special references to the effect on abnormal behavior in mice and rats].
Fujiwara M; Sakurai Y; Kiyota Y; Shimazoe T; Ohta H; Shibata S; Ueki S
Nihon Yakurigaku Zasshi; 1985 Apr; 85(4):259-74. PubMed ID: 2989132
[TBL] [Abstract][Full Text] [Related]
13. Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities.
Lippman W; Pugsley TA
Can J Physiol Pharmacol; 1976 Aug; 54(4):494-509. PubMed ID: 974878
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from Lobelia inflata leaves.
Subarnas A; Tadano T; Oshima Y; Kisara K; Ohizumi Y
J Pharm Pharmacol; 1993 Jun; 45(6):545-50. PubMed ID: 8103103
[TBL] [Abstract][Full Text] [Related]
15. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Worms P; Kan JP; Wermuth CG; Roncucci R; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):241-50. PubMed ID: 3100770
[TBL] [Abstract][Full Text] [Related]
16. Epileptic phenomena induced in the cat by the antidepressants maprotiline, imipramine, clomipramine, and amitriptyline.
Koella WP; Glatt A; Klebs K; Dürst T
Biol Psychiatry; 1979 Jun; 14(3):485-97. PubMed ID: 476233
[TBL] [Abstract][Full Text] [Related]
17. Some central pharmacological effects of (+)- and (-)-oxaprotiline.
Maj J; Rogóź Z; Skuza G; Sowińska H
J Neural Transm Gen Sect; 1990; 80(2):129-43. PubMed ID: 2317315
[TBL] [Abstract][Full Text] [Related]
18. Central nervous effects of a new tricyclic antidepressant (amitriptylinoxide).
Wenzl H; Graf E; Sieck A
Arzneimittelforschung; 1978; 28(10b):1874-9. PubMed ID: 261811
[TBL] [Abstract][Full Text] [Related]
19. [Behavioral effects of a new antidepressant, setiptiline].
Yamada K; Furukawa T
Nihon Yakurigaku Zasshi; 1991 Jan; 97(1):31-9. PubMed ID: 2045013
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCI-2016), a new psychotropic drug with antidepressant activity.
Tobe A; Yoshida Y; Ikoma H; Tonomura S; Kikumoto R
Arzneimittelforschung; 1981; 31(8):1278-85. PubMed ID: 7197535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
